Spectral AI (MDAI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Apr, 2026Executive summary
The annual meeting is scheduled for May 29, 2026, both in-person and virtually, with voting on key proposals and director elections.
Proxy materials are distributed via internet under SEC's "notice and access" rules, with options for paper copies.
Stockholders of record as of April 1, 2026, are eligible to vote, with 31,823,985 shares outstanding.
Voting matters and shareholder proposals
Election of five directors to serve until the next annual meeting.
Ratification of Forvis Mazars, LLP as independent auditor for 2026.
Authorization for reservation and issuance of up to 8,000,000 shares to Hudson Bay under a securities purchase agreement, subject to Nasdaq rules.
Other business may be transacted as properly brought before the meeting.
Board of directors and corporate governance
Board consists of five directors, with a majority deemed independent under Nasdaq rules.
Board committees include Audit, Compensation, Nominating and Corporate Governance, Science and Technology, and Executive Committees.
Leadership structure changed in February 2026, appointing Vincent Capone as CEO and dissolving the Office of the Chairman.
Corporate governance guidelines, code of conduct, and insider trading policy are in place and available on the company website.
Latest events from Spectral AI
- Director elections, auditor ratification, and share issuance to Hudson Bay Master Fund Ltd. on agenda.MDAI
Proxy filing16 Apr 2026 - Shareholders will vote on director elections, auditor ratification, and a significant share issuance.MDAI
Proxy filing16 Apr 2026 - 2025 net loss narrowed, cash rose to $15.4M, and 2026 revenue is forecast at $18.5M.MDAI
Q4 202524 Mar 2026 - Q2 revenue up 76% year-over-year; DeepView commercialization and funding risks persist.MDAI
Q2 20241 Feb 2026 - AI-driven wound care system nears FDA submission, with UK pilots and strong funding support.MDAI
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Q3 revenue up 138% to $8.2M, margins improved, and FDA submission and spin-off plans advance.MDAI
Q3 202416 Jan 2026 - FY 2024 R&D revenue hit $29.6M as DeepView excelled in trials and FDA submission nears.MDAI
Q4 202424 Dec 2025 - AI diagnostics firm seeks up to $50M via Nasdaq offering to fund R&D and repay debt.MDAI
Registration Filing16 Dec 2025 - AI wound diagnostics firm registers 1M shares for resale; no proceeds to company, high risk profile.MDAI
Registration Filing16 Dec 2025